BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20688355)

  • 1. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S; Frkovic-Grazio S; Lamovec J; Serdarevic F; Gurjeva O; Palazzo J; Bilalovic N; Lee LM; Gatalica Z
    Hum Pathol; 2010 Nov; 41(11):1617-23. PubMed ID: 20688355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H; Chen R; Li W; Xu L; Xu L
    Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Jun; 123(6):889-95. PubMed ID: 15899781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR expression and gene copy number in triple-negative breast carcinoma.
    Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
    Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases.
    Nagao T; Gaffey TA; Serizawa H; Sugano I; Ishida Y; Yamazaki K; Tokashiki R; Yoshida T; Minato H; Kay PA; Lewis JE
    Mod Pathol; 2003 Dec; 16(12):1265-72. PubMed ID: 14681328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
    Shao MM; Zhang F; Meng G; Wang XX; Xu H; Yu XW; Chen LY; Tse GM
    Histopathology; 2011 Aug; 59(2):264-73. PubMed ID: 21884205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.